The Asia Factor Whitepaper

How Does a Smart Deal Maker “Play” This Region and Optimize the Capital Raising and Strategic Deal Making Opportunities? Authors: Hayato Watanabe, SVP, Head of Asia Koji Hirabata, Associate Stefanie Gan, Analyst Although their biopharma ecosystem dynamics...

Indication Selection for a Platform Company: The Faustian Dilemma

At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients.  Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value.  Specifically, many...

Key trends impacting Japan partnering

Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies. Doing deals is never easy, no matter the geography. However, it does seem that negotiating with Japanese companies...